Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03697577 · ClinicalTrials.gov registry record

CDK and Body Composition Study

A clinical trial of Breast Cancer, sponsored by Montefiore Medical Center.

Recruiting
Registry status
30
Enrollment target
1
Study location

NCT03697577 is a study of Breast Cancer that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03697577, a study of Breast Cancer, is actively recruiting participants, sponsored by Montefiore Medical Center.

RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to evaluate changes in body composition among patients who are treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or palbociclib).

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST CT scans
  • DIAGNOSTIC_TEST DEXA scan

Study Locations (1)

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-01-08
Est. Completion 2026-12

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT03697577

The ClinicalTrials.gov registry entry for NCT03697577 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which CT scans is the first listed.

NCT03697577 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03697577 about?

NCT03697577 is a clinical study titled "CDK and Body Composition Study". The goal of this study is to evaluate changes in body composition among patients who are treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or palbociclib).

What is the current status of trial NCT03697577?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2019-01-08. Estimated completion is 2026-12.

What conditions does trial NCT03697577 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03697577?

The interventions under investigation include: CT scans (DIAGNOSTIC_TEST), DEXA scan (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03697577?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03697577 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.